Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Earnings Data
Report Date
May 19, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by robust Phase II clinical data (early NASH resolution, antifibrotic signals, 7.5% weight loss at 48 weeks), favorable tolerability, FDA Breakthrough designation, clear alignment with the FDA on Phase III design, completed AUD enrollment, and a strengthened balance sheet with a pro forma cash position (~$340M) providing runway into 2028. Key risks discussed included increased near-term operating expenses and G&A, a widened net loss, reliance on biopsy-driven endpoints (NITs not yet registrational), operational and enrollment execution risks for a large global Phase III, and competitive dynamics in the dual-agonist space. On balance, the positives (clinical differentiation, regulatory progress, funding runway, commercial interest) outweigh the challenges, though execution and funding discipline will be critical as Phase III is initiated.Company Guidance
Strong Phase II MATCH and IMPACT Clinical Results
PEMB demonstrated early NASH resolution at 24 weeks and clear antifibrotic activity at 48 weeks with dose response supporting 1.8 mg focus and evaluation of 2.4 mg. Key noninvasive tests (ELF, liver stiffness, ALT, cT1) improved, and 1.8 mg produced 7.5% mean weight loss at 48 weeks with no plateau.
Favorable Tolerability and Low Discontinuation
Phase II data showed limited GI adverse events and low treatment discontinuation despite absence of titration; GI events were mostly in the first 1–2 months, informing a planned simple one- or two-step titration for Phase III to further improve tolerability.
Regulatory Progress — FDA Alignment and Breakthrough Designation
PEMB received FDA Breakthrough Therapy designation in NASH. End-of-Phase II meeting minutes confirmed alignment with the FDA on key Phase III design elements (population, endpoints, powering), with a biopsy-driven pivotal cohort and AI-assisted histologic assessment planned.
Well-Defined Phase III Design and Powering
Planned pivotal Phase III: ~990 biopsy-confirmed F2/F3 patients (330 per arm: placebo, 1.8 mg, 2.4 mg) powered >90% for co-primary endpoints (NASH resolution without fibrosis worsening OR fibrosis improvement without NASH worsening) at 52 weeks; second ~800-patient NIT cohort; total ~1,800 patients.
Commercial Interest and Market Research Support
Market research of 75 U.S. HCPs showed >70% had a high/very high likelihood to prescribe PEMB; physicians projected use in ~43% of F2 and ~51% of F3 patients and >80% saw PEMB as a first- or second-line option, citing tolerability, straightforward titration, and lean-mass-preserving weight loss as differentiators.
Completed AUD Enrollment Ahead of Schedule and Ongoing ALD Enrollment
Phase II RECLAIM (AUD) enrollment completed in 2025 (top-line data expected Q3 2026); RESTORE (ALD) enrollment is ongoing and expected to complete in 2026, expanding evidence across alcohol-related liver disease indications.
Strengthened Financial Position and Cash Runway
Year-end cash of ~$274M, plus subsequent January financing (registered direct $75M and $8M ATM) yields a pro forma cash position of ~ $340M (approx. +24% pro forma vs year-end). Net proceeds recorded during 2025 totaled ~$208M (≈$174M equity + $35M loan). Company forecasts runway into 2028 to support Phase III plans.
Operational Preparedness and Team Enhancements
Management emphasized hiring of late-stage development, liver disease, and commercial experts; protocol finalization and regulatory planning are advanced, with global trial footprint planned (Americas, Europe, Asia).
ALT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $4.27 | $3.50 | -17.92% |
Nov 06, 2025 | $3.75 | $3.94 | +5.07% |
Aug 12, 2025 | $3.38 | $3.62 | +7.10% |
May 13, 2025 | $6.01 | $5.76 | -4.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Altimmune Inc (ALT) report earnings?
Altimmune Inc (ALT) is schdueled to report earning on May 19, 2026, TBA (Confirmed).
What is Altimmune Inc (ALT) earnings time?
Altimmune Inc (ALT) earnings time is at May 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALT EPS forecast?
ALT EPS forecast for the fiscal quarter 2026 (Q1) is -0.24.